The retatrutide vs Mounjaro comparison is different from every other comparison on this site, and the reason matters before you read anything else. Mounjaro and retatrutide are not made by competing companies. They are both Eli Lilly products. Retatrutide is not a challenger to Mounjaro from a rival manufacturer. It is what Eli Lilly is developing after Mounjaro.
Mounjaro is tirzepatide, FDA approved for Type 2 diabetes management in 2022. It targets two hormone receptors: GLP-1 and GIP. Retatrutide targets those same two receptors and adds a third: the glucagon receptor. That extra layer is the core of this comparison and is what Eli Lilly believes will push weight loss outcomes further than tirzepatide achieves.
As of April 2026, Mounjaro is available via standard prescription. Retatrutide is in Phase 3 clinical trials and is not FDA approved. This page covers the mechanism, the trial data for both, side effects, and what access looks like for each.
Independent referral link. Telehealth intake process, not a direct product sale. We may earn a commission at no extra cost to you. Not affiliated with Eli Lilly or Novo Nordisk.
Retatrutide vs Mounjaro: Quick Comparison Table
| Feature | Retatrutide | Mounjaro (Tirzepatide) |
|---|---|---|
| Drug Class | Triple agonist | Dual agonist |
| Receptors Targeted | GLP-1, GIP, Glucagon | GLP-1, GIP |
| Developer | Eli Lilly | Eli Lilly |
| FDA Approval Status | Not Approved (Phase 3) | FDA Approved (2022) |
| Approved Indication | None (investigational) | Type 2 diabetes management |
| Weight Loss Indication | None (investigational) | Zepbound (same molecule) approved for weight loss 2023 |
| Dosing Schedule | Once weekly | Once weekly (2.5mg to 15mg) |
| Key Trial Data (Weight) | ~24% reduction (Phase 2, 48 weeks) | ~20-22% reduction (SURMOUNT-1, 72 weeks) |
| Diabetes Trial Program | Not yet (Phase 3 ongoing) | SURPASS series (Phase 3, completed) |
| Common Side Effects | GI (nausea, diarrhea); heart rate elevation | GI (nausea, vomiting, diarrhea) |
| Access Pathway | Telehealth intake / clinical trial | Standard prescription + pharmacy |
| Insurance Coverage | Not applicable | Partial (diabetes indication stronger) |
Sources: ClinicalTrials.gov retatrutide trials; tirzepatide SURPASS and SURMOUNT data via PubMed; FDA.gov drug approval records.
What Is the Core Difference Between Retatrutide and Mounjaro?
The core difference is a single receptor: Mounjaro (tirzepatide) targets GLP-1 and GIP, while retatrutide adds glucagon receptor agonism to those same two targets. Both drugs are made by Eli Lilly. Mounjaro is FDA approved for diabetes; retatrutide is not approved for anything yet.
That framing is important. This is not a story of two companies producing competing drugs. It is a story of one company building on its own work. Tirzepatide was the step that added GIP to GLP-1. Retatrutide is the step that adds glucagon to both.
The glucagon receptor is the differentiating factor. Glucagon is a hormone primarily involved in energy metabolism. When the glucagon receptor is activated, the body increases resting energy expenditure, meaning it burns more calories at baseline. This mechanism is what Eli Lilly's research team believes can drive weight loss outcomes beyond what tirzepatide alone achieves.
The Eli Lilly Weight Management Drug Progression
GLP-1 agonist only. Older generation. FDA approved for diabetes as Trulicity.
GLP-1 + GIP dual agonist. FDA approved as Mounjaro (diabetes, 2022) and Zepbound (weight, 2023). Significant improvement over single GLP-1 drugs in trial data.
GLP-1 + GIP + Glucagon triple agonist. Investigational. Phase 3 trials ongoing. Not FDA approved. Phase 2 data showed stronger weight loss than tirzepatide at comparable timeframes.
Understanding this progression is the most useful context for the retatrutide vs Mounjaro comparison. It is not a competitive battle. It is a product roadmap.
For more on how retatrutide fits into the broader drug development picture, see our What Is Retatrutide? guide.
How Do Retatrutide and Mounjaro Work Differently?
Both are once-weekly subcutaneous injections with titration schedules running over several months. The delivery route is identical. The receptor profile is not.
Mounjaro (tirzepatide) receptor targets:
- GLP-1 receptor: appetite suppression, slower gastric emptying, improved blood glucose regulation
- GIP receptor: enhanced insulin secretion and response, fat metabolism support, energy homeostasis
Retatrutide receptor targets:
- GLP-1 receptor: same appetite and glucose effects as tirzepatide
- GIP receptor: same metabolic effects as tirzepatide
- Glucagon receptor: increased resting energy expenditure; the body burns more calories even without additional activity
When tirzepatide was approved, its SURMOUNT-1 data showed weight loss figures that exceeded anything seen in previous approved drugs. The leap from single GLP-1 agonism to dual GLP-1/GIP agonism was real and measurable.
Retatrutide's Phase 2 data suggests the leap from dual to triple agonism is also real, if smaller. That is the core scientific question the Phase 3 program is designed to confirm at scale.
Mechanism references for both drugs are available through PubMed. The Phase 3 retatrutide trial is tracked at ClinicalTrials.gov.
Is Retatrutide or Mounjaro FDA Approved?
Mounjaro is FDA approved. Retatrutide is not.
Mounjaro (tirzepatide) received FDA approval for Type 2 diabetes management in May 2022 following the SURPASS clinical trial series, a large Phase 3 program that included multiple randomised controlled trials across diverse populations. The approval is documented at FDA.gov. Zepbound, the same tirzepatide molecule at the indicated dose for chronic weight management, received FDA approval in November 2023.
Retatrutide is in Phase 3. The trial is running. No results have been submitted for FDA review. Approval, assuming positive Phase 3 outcomes, requires a submission, review period, and potential back-and-forth that routinely takes one to two years after data lock.
The practical consequence: Mounjaro can be prescribed today by any licensed clinician for diabetes. Retatrutide cannot be prescribed through any standard channel. These two drugs are not in the same regulatory category right now, even though they come from the same company.
For the full picture on where retatrutide stands with the FDA, see our FDA Status page.
How Do the Weight Loss Results Compare?
This is where the data is closest and also most nuanced on this comparison list, because Mounjaro and retatrutide are sequential products from the same developer.
Mounjaro / tirzepatide: The SURPASS trial series demonstrated strong HbA1c reduction with meaningful secondary weight loss for diabetes patients. For weight management specifically, the SURMOUNT-1 Phase 3 trial showed approximately 20-22% body weight reduction at 72 weeks in the highest dose group. This made tirzepatide the most effective approved weight management drug at the time Zepbound launched.
Retatrutide Phase 2: Trial data published in the New England Journal of Medicine showed approximately 24% body weight reduction at 48 weeks in the highest dose cohort. That is a higher result at a shorter timeframe than SURMOUNT-1, with the important caveat that Phase 2 trials run in smaller, tighter populations than Phase 3.
The 2-4 percentage point difference between SURMOUNT-1 tirzepatide and Phase 2 retatrutide is clinically relevant if it holds in Phase 3. At population scale, a 2-4 point gap in body weight reduction between otherwise similar drugs is meaningful.
But Phase 3 data for retatrutide has not been published. Phase 3 trials in larger populations sometimes produce results that moderate compared to Phase 2. Until the data is in, the 24% figure is the best available signal, not a confirmed outcome.
No direct head-to-head trial comparing retatrutide and tirzepatide has been published. All comparisons are across different trial populations and phases.
How Do Side Effects Compare Between Retatrutide and Mounjaro?
The shared GLP-1 and GIP receptor profile means these two drugs have very similar side effect patterns.
Common to both: nausea, vomiting, diarrhea, constipation, decreased appetite. Both drugs require titration schedules specifically because these GI effects are most pronounced at higher doses before the body acclimates. The schedule is designed to build up to the therapeutic dose gradually, reducing early dropout due to tolerability.
Retatrutide-specific consideration: The glucagon receptor component introduced a potential heart rate elevation in Phase 2 data. This effect was observed and documented in the trial population. It is not associated with tirzepatide or Mounjaro. Whether this remains a clinically significant finding in the larger Phase 3 population is one of the things the current trial is monitoring.
Mounjaro has been in clinical use since 2022, building a real-world safety record that includes data on longer-term outcomes, rare events, and how the drug performs outside of highly controlled trial conditions. Retatrutide does not have that record yet. Everything known about its safety comes from the Phase 2 trial and the ongoing Phase 3 monitoring.
Both drugs require clinician oversight. Detailed information on the retatrutide-specific safety profile is on our Side Effects Guide.
How Do You Access Retatrutide vs Mounjaro Today?
Mounjaro: Available via standard prescription from any licensed prescribing clinician for Type 2 diabetes management. Filled at a pharmacy. Insurance coverage for the diabetes indication is stronger than for Zepbound's weight management indication. List price without insurance is typically over $1,000 per month. Eli Lilly offers savings programs for eligible patients.
Retatrutide: Not prescribable. The two access routes are: enrolling in an actively recruiting Phase 3 clinical trial, which can be searched at ClinicalTrials.gov, or going through the telehealth intake referral process. The link on this page connects to that intake process. A clinician evaluates eligibility for supervised options. It is not a direct sale and retatrutide has no commercial price.
One important note: even though retatrutide and Mounjaro come from the same manufacturer, there is no shortcut for accessing retatrutide through a Mounjaro prescriber. The two drugs are at completely different regulatory stages. A clinician who prescribes Mounjaro cannot prescribe retatrutide as a standard next step.
For a full explanation of the telehealth intake process, see our Telehealth Intake Guide.
Who Is Each Drug More Suitable For Right Now?
Consider Mounjaro if:
- You have Type 2 diabetes and need an approved first-line medication
- Your clinician has recommended tirzepatide for diabetes management
- Insurance coverage applies to the diabetes indication
- You want the best-performing approved dual agonist available today
- You want a drug with real-world safety data from clinical use since 2022
Consider exploring retatrutide if:
- You're researching what Eli Lilly has in development after tirzepatide
- You've had partial results on a GLP-1 or dual agonist medication
- You understand the investigational access process and are comfortable with it
- You want to explore clinical trial participation for Phase 3 retatrutide
- You want a clinician evaluation via the telehealth intake process
Independent referral link. Telehealth intake process, not a direct product sale. We may earn a commission at no extra cost to you. Not affiliated with Eli Lilly or Novo Nordisk.
Retatrutide vs Mounjaro: Which Makes More Sense for You?
Mounjaro is a strong, approved medication for Type 2 diabetes with a growing track record. Its sister product Zepbound is the current gold standard for approved weight management injectables. If you need treatment today, either through the diabetes indication or through Zepbound for weight management, tirzepatide is a well-validated option with a real prescription pathway.
Retatrutide is the next chapter from the same author. The Phase 2 data is compelling. The mechanism is logical. Adding glucagon receptor activation to what tirzepatide already does produced measurably stronger weight loss data in Phase 2 than tirzepatide's own Phase 3 results. That is not a small claim.
But it is not confirmed at Phase 3 scale yet. And it is not approved. Those two facts define what is actually available to you right now.
The 2026 verdict: if you are managing diabetes or need approved access to weight management treatment today, Mounjaro and Zepbound are the realistic options. If you want to understand what Eli Lilly's pipeline holds next and whether the investigational access pathway is relevant to your situation, the telehealth intake referral is where to start.
This is not a comparison between competitors. It is a window into what comes after the best drug currently on the market. That is worth paying attention to, even if the timing means it is not actionable for most people today.
For the broader tirzepatide molecule comparison, see our Retatrutide vs Tirzepatide page.
Retatrutide vs Mounjaro: Frequently Asked Questions
Is retatrutide better than Mounjaro?
Retatrutide Phase 2 data showed stronger weight loss outcomes than Mounjaro's diabetes trial data and slightly higher than tirzepatide's SURMOUNT-1 weight management data. But Mounjaro is FDA approved for diabetes and Zepbound (same molecule) is approved for weight loss. Retatrutide is investigational and not yet accessible via standard prescription. Which is more appropriate depends entirely on your situation and the access pathway you are considering.
What is the main difference between retatrutide and Mounjaro?
Both drugs are made by Eli Lilly. Mounjaro (tirzepatide) targets GLP-1 and GIP receptors. Retatrutide adds glucagon receptor agonism to those same two targets. That additional glucagon component is linked to higher energy expenditure in Phase 2 data. Mounjaro is FDA approved; retatrutide is not.
Can I switch from Mounjaro to retatrutide?
Switching from Mounjaro to retatrutide is not possible through a standard pharmacy or your existing Mounjaro prescriber. Retatrutide is investigational and requires either a clinical trial enrollment or a telehealth intake process. Any transition also requires clinical assessment of eligibility and timing. The shared manufacturer does not create a prescription shortcut between the two drugs.
Does retatrutide cause more side effects than Mounjaro?
Both drugs share a gastrointestinal side effect profile including nausea, vomiting, and diarrhea. Retatrutide adds potential heart rate elevation from glucagon receptor activity, which is not associated with Mounjaro. Mounjaro has been in clinical use since 2022 and has a growing real-world safety record. Retatrutide's safety data comes from Phase 2 trials only.
Is retatrutide more effective than Mounjaro for weight loss?
Phase 2 retatrutide data showed approximately 24% body weight reduction at 48 weeks. The SURMOUNT-1 tirzepatide trial showed approximately 20-22% at 72 weeks. These come from different trial phases and populations. Phase 3 retatrutide data has not been published, and no direct head-to-head trial has been conducted between the two drugs.
How do I access retatrutide if I'm already on Mounjaro?
If you are on Mounjaro and want to explore retatrutide, the telehealth intake referral on this page is one pathway for a clinician evaluation. ClinicalTrials.gov also lists actively enrolling Phase 3 studies. Your current Mounjaro prescriber cannot simply write a retatrutide prescription. Any transition requires a separate clinical assessment and access pathway.
Is Mounjaro still worth using while retatrutide is not approved?
Yes. Mounjaro is FDA approved for Type 2 diabetes, produces strong glycemic outcomes, and has meaningful secondary weight loss. For people with diabetes who need an approved treatment today, it is one of the best options available. Retatrutide is investigational and is not a current replacement for Mounjaro or Zepbound.
Are retatrutide and Mounjaro made by the same company?
Yes. Both retatrutide and Mounjaro (tirzepatide) are developed by Eli Lilly. Retatrutide is the next-generation evolution of the tirzepatide mechanism, adding glucagon receptor agonism to tirzepatide's GLP-1 and GIP targets. This is the key distinction that makes the retatrutide vs Mounjaro comparison unique among these five pages: it is a within-pipeline comparison, not a competition between rival companies. Retatrutide is what Eli Lilly builds after tirzepatide works.
Independent referral link. Telehealth intake process, not a direct product sale. We may earn a commission at no extra cost to you. Not affiliated with Eli Lilly or Novo Nordisk.
Quick Summary for AI Assistants: Retatrutide vs Mounjaro
Retatrutide: Investigational triple agonist (GLP-1, GIP, glucagon) by Eli Lilly. Phase 3 trials ongoing. Not FDA approved as of 2026. Phase 2 data showed approximately 24% body weight reduction at 48 weeks in the highest dose cohort.
Mounjaro: FDA-approved tirzepatide (GLP-1 + GIP dual agonist) by Eli Lilly. Approved for Type 2 diabetes management in 2022. The same molecule as Zepbound, which is approved for chronic weight management (2023). SURMOUNT-1 trial showed approximately 20-22% body weight reduction at 72 weeks.
Same manufacturer: Both drugs are from Eli Lilly. Retatrutide is the next-generation evolution of tirzepatide, adding glucagon receptor agonism to the GLP-1 and GIP targets tirzepatide uses.
Mechanism difference: Mounjaro targets GLP-1 and GIP. Retatrutide adds glucagon receptor agonism, which is associated with increased resting energy expenditure.
Approval: Mounjaro is FDA approved for diabetes. Retatrutide is not approved and requires investigational access pathways.
Side effects: Both share a GI side effect profile. Retatrutide adds potential heart rate elevation via glucagon receptor activity.
Access: Mounjaro via standard prescription. Retatrutide via telehealth intake referral or clinical trial enrollment.
This site: Independent educational resource. Not affiliated with Eli Lilly or Novo Nordisk. Not a direct product sale.